|
Best overall response
|
huKS-IL2 dosing cohort, mg/m2
| |
|---|
|
0.5
|
1.0
|
2.0
|
3.0
|
4.0
|
Overall
|
|---|
|
(n=3)
|
(n=4)
|
(n=6)
|
(n=6)
|
(n=7)
|
(n=26)
|
|---|
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
|---|
|
n (missing)
|
3 (0)
|
3 (1)
|
6 (0)
|
6 (0)
|
7 (0)
|
25 (1)
|
|
CR
|
0
|
0
|
0
|
0
|
0
|
0
|
|
PR
|
0
|
0
|
0
|
0
|
0
|
0
|
|
SD
|
1 (33.3)
|
1 (33.3)
|
2 (33.3)
|
3 (50.0)
|
3 (42.9)
|
10 (40.0)
|
|
PD
|
2 (66.7)
|
2 (66.7)
|
4 (66.7)
|
2 (33.3)
|
4 (57.1)
|
14 (56.0)
|
- Notes: Includes subjects who withdrew due to PD prior to an objective tumor response assessment. One subject discontinued the study due to treatment-emergent adverse events without any post-baseline disease assessment.
-
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
